Research Roundup: Update on Zika R&D
In this regular feature on Breakthroughs, we highlight the most promising Zika virus vaccine, drug, and diagnostic candidates as well as vector control approaches.
Sign up to receive news and updates from GHTC.
In this regular feature on Breakthroughs, we highlight the most promising Zika virus vaccine, drug, and diagnostic candidates as well as vector control approaches.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
The Administration announced that it will transfer nearly $600 million in remaining Ebola funds to fight the growing threat of Zika virus. But many questions remain. Where is the money going? What accounts is it coming from? And what does this mean for the Global Health Security Agenda?
After four successful Phase 3 clinical trials enrolling more than 3,500 patients in 18 countries, the European Medicines Agency (EMA) has granted Pyramax® Granules, a pediatric malaria medicine, a positive opinion under Article 58—a mechanism through which the EMA reviews and issues a scientific opinion on products that are not intended for use in Europe.